Search Results for “ breast cancer ” – Page 6 – media

BioNTech, DualityBio Move ADC into Phase III for HER2-Low Breast Cancer

By Kate Goodwin Pictured: 3D rendering of antibody-drug conjugate/iStock, Love Employee BioNTech’s licensed antibody-drug conjugate is moving on to Phase III testing in a potential effort to challenge AstraZeneca and Daiichi Sankyo’s blockbuster Enherto in a heavily treated breast cancer subpopulation. DualityBio, BioNTech’s partner and the ADC’s creator, posted the trial plans Wednesday. BioNTech added the ADC, DB-1303, to its portfolio in April 2023 when it paid China’s DualityBio $170 million upfront for rights to it plus a second preclinical asset. Another $1.5 billion is on the line in milestone payments, plus tiered royalties. DB-1303 will be pitted against chemotherapy in the open-label Phase III for patients with HER2-low, HR+ metastatic breast cancer patients whose disease has progressed despite endocrine therapy. ADC therapy is like a targeted missile for cancer, with an antibody targeted to deliver the cancer killing payload. DB-1303 is a topoisomerase-1 inhibitor. Phase I/II trial results showed ...
- Source: drugdu
- 108
- September 5, 2023
Healthy Breast Fat may Protect Against Invasive Breast Cancer

Researchers have found a possible explanation as to why higher breast density and older age increase the risk of breast cancer. In an innovative study, researchers at the Turku Bioscience Centre, InFLAMES Flagship of the University of Turku, and Turku University Hospital, Finland, have made an extraordinary discovery that turns conventional wisdom on its head. Their findings reveal that healthy fat cells in the breast, also known as adipocytes, secrete a potent factor called IGFBP2, which acts as a barrier against invasive breast cancer progression. Dr. Emilia Peuhu (Study Key Collaborator) said, “Adipocytes generally get a bad rap for promoting cancer progression, but this study demonstrates that healthy breast fat can play a protective role in the maintenance of tissue homeostasis and cancer containment. It’s time to re-evaluate our assumptions and recognize the important role of these unsung heroes.” Breast cancer patients who experience the transition ...
- Source: drugdu
- 104
- July 18, 2023
Dana-Farber research supports FDA approval of new therapy for metastatic breast cancer

Sacituzumab govitecan, a novel antibody drug-conjugate therapy was granted accelerated approval on February 3, 2023 by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic HR+, HER2- breast cancer. The FDA action was based on the results of TROPICS-02, a study in which Dana-Farber Cancer Institute’s Sara Tolaney, MD, MPH, helped lead and which was presented at the European Society of Medical Oncology annual meeting in September 2022 as well as the American Society of Clinical Oncology meeting in June 2022. Researchers reported that the sacituzumab govitecan produced a statistically significant improvement in overall survival rates compared to chemotherapy. The overall survival rate for patients taking part in the global phase 3 study was 14.4 months for those who received sacituzumab govitecan and 11.2 for those given chemotherapy. The sacituzumab arm of the study also showed superior response rates as well as prolonged median progression free survival ...
- Source: drugdu
- 150
- June 6, 2023
Research finds alternating estrogen and anti-estrogen therapies effective in treating metastatic breast cancer

Advanced or metastatic estrogen receptor-positive (ER+) breast cancer is commonly treated with drugs that block the estrogen receptor. However, estrogens that stimulate the receptor can also be effective. Building on their previous studies, researchers at Dartmouth Cancer Center recently concluded a Phase II clinical trial aimed to test the efficacy of alternating between estrogen stimulation and estrogen deprivation in patients with metastatic ER+ breast cancer, and to identify tumor characteristics that predict who might benefit from this strategy. The results, newly published ahead of print in Clinical Cancer Research, support cyclical estrogen/anti-estrogen therapy as a promising strategy to treat advanced/metastatic ER+ breast cancer. The POLLY trial stands for “Phase II study of Pre-emptive oscillation of ER activity levels through alternation of estradiol/anti-estrogen therapies prior to disease progression in ER+/HER2- metastatic or advanced breast cancer.” Among 19 patients enrolled in the trial, 3 (16%) experienced tumor shrinkage during cyclical treatment and ...
- Source: drugdu
- 125
- May 17, 2023
Dietary supplement helps combat resistance in breast cancer, finds study

Many cancer therapies do not produce the hoped-for results. A common reason for this is that the tumors develop resistance to the medications. This is the case, for example, with alpelisib, a drug that has been approved for use in Switzerland for the past few years as a treatment for advanced breast cancer. A research group at the Department of Biomedicine of the University of Basel has now discovered that the loss of the neurofibromin 1 (NF1) gene leads to a reduced response to alpelisib. The researchers also found that the dietary supplement N-acetylcysteine restores the sensitivity of cancer cells to this treatment. The findings have been published in the journal Cell Reports Medicine on April 11. Loss of gene triggers resistance At the moment, patients with advanced and metastatic breast cancer lack effective treatment options. The PI3K signaling pathway is often overactive in breast cancer due to mutations promoting tumor ...
- Source: drugdu
- 140
- April 12, 2023
All hormonal contraceptives ‘carry small increased risk of breast cancer’

Research finds use of progestogen is associated with a 20-30% higher risk but this falls after no longer taking it All types of hormonal contraceptives carry a small increased risk of breast cancer, according to research establishing a link with progestogen pills for the first time. The use of progestogen is associated with a 20-30% higher risk of breast cancer, data analysis by University of Oxford researchers has established. This builds on previous work showing that use of the combined contraceptive pill, which contains oestrogen and progestogen, is associated with a small increase in the risk of developing breast cancer that declines after stopping taking it. Claire Knight of Cancer Research UK, which funded the study, said the risk was small and should not discourage most people from taking the pill. She said: “Women who are most likely to be using contraception are under the age of 50, where the risk of ...
- Source: drugdu
- 121
- March 22, 2023
Novartis’s Alpelisib Treats Advanced Breast Cancer

Finding the ultimate treatment for breast cancer is still a dream for all the pharma companies worldwide. At present, only hormonal therapy, Pfizer’s Ibrance, Eli Lilly’s Verzenio and Novartis’s Kisqali are available for breast cancer treatment.
- Source: Reuters
- 890
- August 24, 2018
breast cancer Company Insight Novartis
Night Shifts could Potentially Increases the Risk of Breast Cancer

More than 2.5 million people work night-shifts. In 2007, the International Agency for Research on Cancer (IARC) reported that working shifts generally disturbs momentum classified as being “probably carcinogenic to humans”.
- Source: MedicalNewsBulletin
- 789
- July 2, 2018
breast cancer cancer Researches
Canadian Scientists Find Blocking Certain Proteins can Avert Breast Cancer

Breast Cancer appears when unusual cells start growing in breast tissue and can affect both women and men. It was estimated that in the U.S. alone there will be a total of 330,080 new cases of breast cancer in women and about 2,550 in men by the end of 2018.
- Source: MedPageToday
- 827
- June 21, 2018
breast cancer Researches
Blood Test to Predict Drug Activity Against Breast Cancer

At present, breast cancer patients need to wait for nearly two to three months to find out via a scan whether palbociclib is working. This new test could detect the circulating tumor DNA which enters the bloodstream. By measuring and comparing PIK3CA levels in a blood test before and 15 post palbociclib therapy, one could predict the effectiveness of the drug.
- Source: Ddu
- 886
- June 7, 2018
blood test breast cancer Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.